CCL20 and liver dysplastic nodule: Consistent with this finding, we also observed a significant decrease in CCL20 expression in the kidneys of diabetic eNOS-/- mice treated with the KCa3.1 blocker TRAM34 compared to the diabetic control group (P<0.05, Fig. 3B, E and F).These data suggest that KCa3.1 contributes to the production of CCL20 in DN.